Method for treating skin diseases using a humanized antibody that binds to vimentin
Inventors
Kim, Yoon-Won • PARK, Sungman • Kim, Min Soo
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11649277-B2
Publication Date
2023-05-16
Expiration Date
Abstract
A method of treating skin diseases by administering a pharmaceutical composition including a humanized antibody which binds to vimentin.
Core Innovation
The invention provides a method for treating or ameliorating skin disease by administering or applying a pharmaceutical or cosmetic composition containing a humanized antibody or fragment thereof. The humanized antibody or fragment specifically binds to a peptide of SEQ ID NO: 1, described as a vimentin-derived peptide, and the target is extracellularly expressed in affected skin but not in normal tissues.
The disclosed antibody includes defined variable-region features that specify antigen binding recognition, including CDR and framework region constraints. The document describes heavy-chain and light-chain CDR sequence constraints using specified SEQ ID numbers, together with framework-region (FR1–FR4) sequence constraints provided by additional SEQ ID numbers, and includes humanized formats and antibody fragments such as Fab, Fab′, F(ab′)2, scFv, and dsFv.
The document states that the humanized antibody (hzVSF) is associated with safety and low immunogenicity relative to FDA-approved antibodies, with immunogenicity reduction related measurements. It also describes extracellular vimentin-derived peptide expression across multiple skin diseases using immunohistochemistry and reports clinical efficacy outcomes across conditions including psoriasis, lichen simplex chronicus, nummular eczema, eczema/atopic dermatitis, dermatitis, and related conditions.
Claims Coverage
The provided independent claims center on a humanized antibody or fragment specifically binding a peptide of SEQ ID NO: 1, applied in either a pharmaceutical composition or a cosmetic composition, with two inventive-feature themes repeated across the claims.
Humanized antibody or fragment specifically binding SEQ ID NO: 1 for pharmaceutical treatment
A method for treating a skin disease comprising administering or applying a pharmaceutical composition comprising a humanized antibody or fragment thereof which specifically binds to a peptide of SEQ ID NO: 1.
Treatment limited to a defined set of skin diseases
The skin disease is selected from the group consisting of pityriasis rosea, lichen simplex chronicus, nummular eczema, eczema, molluscum contagiosum, psoriasis, verruca vulgaris, atopic dermatitis, and allergic contact dermatitis.
Humanized antibody or fragment specifically binding SEQ ID NO: 1 for cosmetic amelioration
A method for ameliorating a skin disease comprising administering or applying a cosmetic composition comprising a humanized antibody or fragment thereof which specifically binds to a peptide of SEQ ID NO: 1.
Amelioration limited to a defined set of skin diseases
The skin disease is selected from the group consisting of pityriasis rosea, lichen simplex chronicus, nummular eczema, eczema, molluscum contagiosum, psoriasis, verruca vulgaris, atopic dermatitis, and allergic contact dermatitis.
Coverage centers on compositions containing a humanized antibody or fragment specifically binding a peptide of SEQ ID NO: 1, used for pharmaceutical treatment or cosmetic amelioration. The claims further restrict the covered conditions to the same defined group of skin diseases.
Stated Advantages
Safety and low immunogenicity relative to FDA-approved antibodies, supported by immunogenicity-related measurements.
Extracellular vimentin-derived peptide expression in affected skin, supporting targeted binding in skin diseases.
Clinical efficacy outcomes are described for hzVSF across multiple listed skin conditions.
Documented Applications
Treating skin diseases including pityriasis rosea, lichen simplex chronicus, nummular eczema, eczema, molluscum contagiosum, psoriasis, verruca vulgaris, atopic dermatitis, and allergic contact dermatitis using a pharmaceutical composition containing a humanized antibody or fragment that specifically binds SEQ ID NO: 1.
Ameliorating skin diseases including pityriasis rosea, lichen simplex chronicus, nummular eczema, eczema, molluscum contagiosum, psoriasis, verruca vulgaris, atopic dermatitis, and allergic contact dermatitis using a cosmetic composition containing a humanized antibody or fragment that specifically binds SEQ ID NO: 1.
Interested in licensing this patent?